ESC Congress 2025 has released twenty-eight late-breaking trials and science sessions to be presented in August 2025.

The congress is set to take place from the 29th August to 1st September at IFEMA - Fiera de Madrid. Access the full programme here.

Late-Breaking Clinical Science: Inflammation and Immune Biomarkers in Cardiovascular Risk Prediction

Friday 29th August, 08:15am – 09:45am (CEST)

• Interleukin-6 and cardiovascular prognosis in apparently healthy individuals – Presented by Berkan Kurt
• Coronary and systemic inflammation: the ORFAN study – Presented by Kenneth Chan
• hsCRP and Long-term CV Outcomes among SMuRF-Less Women – Presented by Paul M Ridker
• C-reactive protein and cardiovascular risk in the general population – Presented by Florian Kahles
• THYM-AF Study: T-Cell Subsets and Atrial Fibrillation
• LoDoCo2: Effect of Colchicine on Clonal Hematopoiesis and Inflammatory Biomarkers – Presented by N Mohammadnia

Late Breaking Clinical Science: Valvular Heart Disease

Friday 29th August, 11:00am – 12:00pm (CEST)

• LAA-CLOSURE - Prophylactic surgical closure of the LAA in SAVR – Presented by Tuomas Kiviniemi
• TRISCEND II trial: TTVR outcomes by baseline TR severity – Presented by Philipp Lurz
• VANTAGE-30-Day and 1-Year Outcomes – Presented by Nicolas van Mieghem
• AI-based quantification of mitral regurgitation with 3D TOE – Presented by Carlo Federico Guarino

Late-Breaking Clinical Trials: Hypertension

Friday 29th August, 11:00am – 12:00pm (CEST)

• RETREAT-FRAIL: A randomized controlled clinical trial on the effects of reduction of antihypertensive treatment in very old frail patients – Presented by Athanase Benetos
• OUTREACH - adherence to treatment and blood pressure control – Presented by Maciej          Tomaszewski
• AIMHY-INFORM: Dual Therapy Arm – Presented by Spoorthy Kulkarni
• Novel Triple Single-Pill for Uncontrolled Hypertension – Presented by Vagner Madrini

Late-Breaking Clinical Science: Cardiogeriatrics and Frailty

Friday 29th August, 13:45pm – 15:00pm (CEST)

• PIpELINe trial-Lifestyle Intervention after Myocardial Infarction – Presented by Elisabetta Tonet
• LOSE-AF: Weight Loss in Older Patients with Atrial Fibrillation – Presented by Rohan  Wijesurendra
• PCI in frail patients undergoing TAVI - A NOTION-3 substudy – Presented by Hanna      Ratcovich
• SENIOR-RITA Frail Analysis – Presented by Vijay Kunadian
• FIRE trial: 3-year results – Presented by Simone Biscaglia

Late Breaking Clinical Science: Global Insights and Outcomes in Heart Failure

Friday 29th August, 16:15pm – 17:15pm (CEST)

• ESC HF III Registry - primary analysis: outcomes – Presented by Lars Lund
• Temporal Trends in HF Outcomes – Presented by Jong-Chan Youn
• THESUS HF II Acute Heart Failure in Africa – Presented by Karen Sliwa
• Early initiation of disease-modifying therapy in patients with suspected heart failure – Presented by Kieran Docherty

Late-Breaking Clinical Science: Coronary Risk and Outcomes

Friday 29th August, 16:15pm – 17:15pm (CEST)

• Cardiovascular risk in patients classified according to the Universal Definition of Myocardial Infarction – Presented by Andrew Chapman
• Medication persistence and mortality in SWEDEHEART STEMI patients with and without standard modifiable risk factors – Presented by Suzanne Robyn Avis
• Monitoring treatment of myocardial infarction in Europe – EuroHeart Annual report 2025 – Presented by David Erlinge
• Kidney function and coronary artery disease – Presented by Lars Ryden

Late-Breaking Clinical Trials: Recent Advances in CIED Therapies

Friday 29th August, 16:15pm – 17:15pm (CEST)

• Comparison between LBBAP and RVP in young adults – Presented by Matteo Bertini
• PhysioSync-HF: Conduction system vs. biventricular pacing for cardiac resynchronization in heart failure with reduced ejection fraction – Presented by Andrew Zimerman
• CAAN-AF: Cardiac Resynchronization Therapy and AV Node Ablation in Heart Failure with Reduced Ejection Fraction and Atrial Fibrillation – Presented by Prashanthan Sanders
• PRAETORIAN/ATLAS: Inappropriate shock with S-ICD vs. transvenous ICD – Presented by William McIntyre

Late-Breaking Clinical Science: Cardio-Oncology

Saturday 30th August, 08:15am – 09:45am (CEST)

• Incidence, risk-factors & prognosticators of ICI-myocarditis in the French population – Presented by Joe Elie Salem
• PRADA II: Sacubitril-Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy – Presented by Torbjorn Omland
• Menopause modulates vascular toxicity of docetaxel – Presented by Piotr Szczepaniak
• EMPATICC: Optimized Heart Failure Therapy in Terminal Cancer to Improve Self Care Ability – Presented by Markus           Anker
• Predictors and Risk Score for Immune Checkpoint-Inhibitor-Associated Myocarditis Severity – Presented by Joe Elie Salem
• NT-proBNP Guide – Presented by Bonnie Ky

Late-Breaking Clinical Trials: Antithrombotic Strategies and PCI Advances

Saturday 30th August, 11:00am – 12:00pm (CEST)

• The PARTHENOPE Trial: Personalized vs Standard DAPT after PCI – Presented by Giovanni Esposito
• TADCLOT- Twice A Day CLOpidogrel vs. Ticagrelor post STEMI – Presented by Abdul Hakeem
• Device success in the Multivessel TALENT trial – Presented by Patrick Washington Serruys
• APERITIF trial – Presented by Etienne Puymirat

Late-Breaking Clinical Trials: Artificial Intelligence in Cardiology

Saturday 30th August, 11:00am – 12:00pm (CEST)

• Heart failure management with AI: the ASSIST-HF SIRIO trial – Presented by Diana A Gorog
• TRICORDER: Triple Cardiovascular Disease Detection with an Artificial Intelligence-enabled Stethoscope: A Cluster Randomised Controlled Trial and Implementation Study – Presented by Patrik Bachtiger
• AI-Gatekeeper: a randomized controlled trial of AI-based screening vs. usual care for suspected coronary artery disease – Presented by Sunga Bae
• FIND-AF: Machine learning guided atrial fibrillation screening – Presented by Ramesh Nadarajah

Late-Breaking Clinical Trials: Vaccinations in Cardiovascular Prevention

Saturday 30th August, 13:45pm – 15:00pm (CEST)

• KP-VACCINATE: Cardiovascular Focused Messaging for Influenza Vaccination – Presented by Ankeet            Bhatt
• DANFLU-2: High-Dose vs. Standard-Dose Influenza Vaccine and Cardio-Respiratory Outcomes in Older Adults – Presented by Tor Biering-Sorensen
• DAN-RSV: RSVpreF vaccine for preventing cardiorespiratory hospitalizations – Presented by Tor Biering-Sorensen
• Population Assessment of Influenza and Disease Activities – Presented by Xin Du
• Impact of a pneumococcal vaccination incentive campaign – Presented by Francois Roubille

Late Breaking Clinical Science: Aortic Stenosis

Saturday 30th August, 17:30pm – 18:30pm (CEST)

• IPD Meta-Analysis of Contemporary Trials Comparing TAVI versus SAVR – Presented by Sebastian Ludwig
• 2 Year outcomes from the NOTION-2 trial – Presented by Troels Hojsgaard Jorgensen
• EVOLVED - Myocardial Fibrosis Burden and Early Intervention in Patients with Asymptomatic Severe Aortic Stenosis – Presented by Neil Craig
• Impact of Cerebral Embolic Protection on Cognition: experience from BHF PROTECT-TAVI

Late-Breaking Clinical Trials: Cardiovascular Risk and Prevention

Saturday 30th August, 17:30pm – 18:30pm (CEST)

• Biomarker-guided risk management following acute coronary syndromes – Presented by Robert       Doughty
• ANDAMAN - Aspirin twice a day and Acute Coronary Syndrome – Presented by Jean-Guillaume Dillinger
• CAC CV-PREVITAL Coronary Artery Calcium Scoring in primary prevention – Presented by Giuseppe Ferrante
• CONFIDENCE: ambulatory blood pressure monitor substudy – Presented by Muthiah Vaduganathan

Late-Breaking Basic & Translational Science

Sunday 31st August, 08:15am – 09:45am (CEST)

• Treating TImothy Syndrome (TTS)
• LOYinCVD - Loss of Y chromosome signatures in human cardiovascular disease – Presented by Andreas Michael Zeiher
• VasoAlergo – Presented by Danila Gurgone
• Advanced 3D bioprinting of functional human cardiac tissue: Implications for modelling myocardial infarction and scar-related ventricular tachycardia – Presented by Tahel Kerem
• RP-CAD: Role of Reticulated platelets in CAD – Presented by Dario Bongiovanni
• CRISPR activation to treat cardiomyopathy – Presented by Enrique Lara-Pezzi
• MICRO-CAP: Microplastics in Coronary Atherosclerotic Plaques – A Postmortem Human Study – Presented by Shanshan Zhou
• Semaglutide promotes vascular repair mechanisms – Presented by Brady Park

Late-Breaking Clinical Science: Cardiometabolic Medicine

Sunday 31st August, 08:15am – 09:45am (CEST)

• CONFIDENCE: Results by KDIGO risk category – Presented by Muthiah Vaduganathan
• SGLT2i and AF – Presented by Jamschid Sedighi
• SURMOUNT-5: Tirzepatide compared to Semaglutide in obesity for 10-year CVD risk reduction – Presented by Mamas Mamas
• Semaglutide is associated with lower risk of cardiovascular events compared with tirzepatide in patients with overweight or obesity and ASCVD and without diabetes in routine clinical practice – Presented by Lauren Wilson
• Semaglutide and Tirzepatide in Patients with Heart Failure with Preserved Ejection Fraction – Presented by Nils Kruger
• STRIDE Outcomes by Sexl – Presented by Subodh Verma

Late Breaking Clinical Science: Cardiogenic Shock and Cardiac Arrest

Sunday 31st August, 11:00am – 12:00pm (CEST)

• Age Analysis of the MCS in CS Meta Analysis – Presented by Uwe Zeymer
• Long-term Outcomes of the DanGer Shock Trial – Presented by Jacob Eifer Moller
• Centralization of CS care and MCS use – Presented by Benedikt Schrage
• The REBOARREST Trial, a randomized controlled trial on aortic occlusion during cardiac arrest – Presented by Jostein Brede

Late-Breaking Clinical Science: Therapeutic Innovations in Heart Failure

Sunday 31st August, 11:00am – 12:00pm (CEST)

• RELAXIN-LA in worsening HFpEF – Presented by Jeffrey Testani
• Effect of finerenone on the plasma proteome: a FINEARTS-HF analysis – Presented by Mario Berger
• MRA response score in HFrEF – Presented by Nicolas Girerd
• Main 3-Year Outcomes of CASTLE-HTx – Presented by Christian Sohns

Late-Breaking Clinical Science: Hypertension

Sunday 31st August, 13:45pm – 15:00pm (CEST)

• Benefit-harm trade-offs of intensive blood pressure control on cardiovascular and renal outcomes: an individual participant data analysis of six pivotal randomized controlled trials – Presented by Yingxian Sun
• Duration of blood pressure treatment and risk of major cardiovascular events – Presented by Kazem              Rahimi
• Impact of Aldosterone Dysregulation on Lorundrostat Efficacy – Presented by Luke Joseph Laffin
• ADEL: A population-based study of clinical outcomes of aldosterone dysregulation – Presented by Reimar W Thomsen
• Sacubitril/Allisartan in hyperuricemia – Presented by Wei Zhang

Late-Breaking Clinical Science: Cardiomyopathies

Sunday 31st August, 16:15pm – 17:15pm (CEST)

• A Phase 2 Trial of Trientine for Hypertrophic Cardiomyopathy – Presented by Christopher Miller
• EMORI-HCM Electro-Mechanically Optimised RVP For oHCM – Presented by Jagdeep Singh Mohal
• REDWOOD-HCM, SEQUOIA-HCM and FOREST-HCM trials: Incidence and impact of atrial fibrillation in oHCM with aficamten – Presented by Ahmad Masri
• Initial findings from MaesTTRo – Presented by Martha Grogan

Late-Breaking Clinical Trials: Advances in Heart Failure Care

Sunday 31st August, 16:15pm – 17:15pm (CEST)

• Lifetime Benefits of Combination Therapy in HFpEF – Presented by Muthiah Vaduganathan
• SUMMIT - HFpEF-ABA Score for enrichment – Presented by Milton Packer
• LOT-MDR: Loop diuretic dose intensification versus adjuvant thiazide for diuretic resistance in acute heart failure – Presented by Zachary                Cox
• ENVAD-HF: sacubitril/valsartan in Heartmate 3 LVAD recipients – Presented by Maja Cikes

Late-Breaking Clinical Science: Cardiovascular Health in Women

Sunday 31st August, 17:30pm – 18:30pm (CEST)

• PRESAP Outcomes – Presented by Sabha Bhatti
• Timing, clustering, mortality, sex differences of CVD – Presented by Amelie Ohlrogge
• Sex differences in Extended Follow-up of the FLAVOUR trial – Presented by
• SPEAR-PPHT Swiss- Persistent Elevated Arterial pRessure in PostPartum Hypertension – Presented by Thenral Socrates

Late-Breaking Clinical Trials: Coronary Artery Disease and Interventions

Sunday 31st August, 17:30pm – 18:30pm (CEST)

• MACROS-2: RCT of ESC 0/1 versus 0/3 hour ADP for suspected ACS – Presented by James Hatherley
• Complete revascularisation versus usual care in non-STEMI with multivessel disease: results from the SLIM study – Presented by Tobias Pustjens
• PANTHER - P2Y12 inhibitor or Aspirin moNoTHERapy as secondary prevention in patients with coronary artery disease – Presented by Marco Valgimigli
• PIONEER IV trial primary report – Presented by Patrick Washington Serruys

Late-Breaking Clinical Science: Lipids and Cardiovascular Risk

Monday 1st September, 08:15am – 09:45am (CEST)

• LipoaScreen – cascade screening for lipoprotein(a) – Presented by Jonas Brinck
• Triglyceride lowering after MI – Presented by Jessica Schubert
• NATURE-LEGACY: Long term legacy benefit of Lowering LDL and SBP – Presented by Brian A Ference
• Obicetrapib and cardiovascular events – Presented by Stephen                  Nicholls
• GAELp(a): National Registry on Lp(a) and Cardiovascular Risk in Argentina – Presented by Nicolas Federico Renna
• Carotid plaques stabilization and regression with evolocumab – Presented by Tiziana Claudia Aranzulla

Late-Breaking Clinical Science: Cardiovascular Imaging and Artificial Intelligence

Monday 1st September, 11:00am – 12:00pm (CEST)

• Fused Echocardiographic and Clinical Deep Learning model for Cardiac Amyloidosis Detection – Presented by Jeremy Slivnick
• AI-enabled nationwide opportunistic screening of non-contrast chest CT for death and cardiovascular outcomes – Presented by Tzung-Dau        Wang
• Second-line testing in patients with stenosis on CCTA – Presented by Laust Dupont Rasmussen
• Culprit Lesion and hemorrhagic STEMI – Presented by Martin Reindl

Late-Breaking Clinical Trials: Atrial Fibrillation Ablation and Rhythm Control

Monday 1st September, 11:00am – 12:00pm (CEST)

• STEEER-AF cluster randomised trial by the ESC and EHRA – Presented by Dipak  Kotecha
• EXCAPE-AF: Extended cryoballoon vs. standard cryoballoon vs. radiofrequency ablation in persistent atrial fibrillation – Presented by Min Soo Cho
• Nanosecond PFA vs RFA for Paroxysmal Atrial Fibrillation – Presented by Yumei Xue
• SINGLE SHOT CHAMPION Trial - Autonomic effects and ablation success after pulsed field and cryoballoon ablation – Presented by Laurent Roten

Late-Breaking Clinical Science: Stroke Prevention

Monday 1st September, 13:45pm – 15:00pm (CEST)

• ACST-2 - 15-year results of stroke prevention for carotid stenting vs endarterectomy – Presented by Alison Halliday
• Outcomes in Patients with High Stroke Risk: A Sub-analysis of the OPTION Clinical Trial – Presented by Oussama Wazni
• Atrial Fibrillation Density Increases the Risk of Ischemic Stroke – Presented by Lindsey Rosman
• Asymptomatic atrial fibrillation detected in electrocardiograms with deep learning methods – Presented by Arjun Butani
• NOAH-AFNET 6 - Effects of anticoagulation or placebo in patients with device-detected atrial fibrillation and multiple stroke risk factors: A win ratio and win odds analysis of the NOAH-AFNET 6 trial – Presented by Nina Becher

Late Breaking Clinical Science: AI Driven Cardiovascular Biomarkers and Clinical Decisions

Monday 1st September, 15:15pm – 16:15pm (CEST)

• PECTUS-AI: AI-based identification of high-risk plaques – Presented by Rick Volleberg
• Feasible machine learning for non-ST-segment myocardial infarction – Presented by Arnaud                 Champetier
• Prognostic value of AI-QCT vs standard CT reads – Presented by Alexander van Rosendael
• Graph Neural Network Automation of Anticoagulation Decision-Making – Presented by Joshua Lampert

Late-Breaking Clinical Science: Atrial Fibrillation Screening and Management

Monday 1st September, 15:15pm – 16:15pm (CEST)

• AF screening yield according to methodology and population characteristics – Presented by Lucas Xing
• Heart Failure in AF patients – Presented by Bernadette Corica
• FARADISE Global Registry: 1-year Clinical Effectiveness of Pulsed Field Ablation for Atrial Fibrillation – Presented by Lucas                  Boersma
• EAST-AFNET4 - Atrial fibrillation burden on early rhythm-control and cardiovascular events in the EAST-AFNET 4 AF trial – Presented by Ulrich Schotten

References

ESC 365. Programme. 2025. https://esc365.escardio.org/esc-congress/programme?text=&docType=All&days=2025-08-29&session_type=Late-Breaking%20Science&page=1&vue=cards (accessed 09 July 2025).